**3. Discussion**

"If it were not for the great variability among individuals, medicine might as well be a science and not an art" with these words the famous Canadian physician Sir William Osler anticipated and acknowledged the concept of personalized medicine since the nineteenth century.

Personalized medicine aims to optimize and tailor preventive and therapeutic approaches in favor of the best outcome for each patient, by using genetics, proteomics, and biological information, including biomarkers [34]. It attempts to sub-categorize patients into different groups according to their "molecular make up", i.e. using biomarkers.

Here we have used a rat model of liver metastasis to identify genes with importance for organ colonization, which could be used as biomarkers or therapeutic targets.

The selected model for this experiment is characterized by a defined metastatic proliferation-onset in rat liver after intra-portal inoculation of CC531 cancer cells. Consequently, this allows exploring the chronological modulation of gene expression, from the very beginning of cancer cell homing into the liver to their final colonization of the whole organ. The technique of cancer cell reisolation from rat liver permitted, for the first time, monitoring the expression profile of numerous candidate genes from the whole genome in a time-dependent manner.

The initial observation of these studies was based on cDNA microarray analysis of CC531 colon cancer cells, which allowed selecting candidates from gene families with significant up- or down-regulation. These candidates were further analyzed by different *in vitro* studies.

We have been focusing on the detection and evaluation of biomarkers for the last decades [33, 35–43]. From the several gene groups, which were highly modulated in expression during liver colonization we focused on two families. Both were characterized by dramatic initial changes in expression, with claudins being down modulated and IGFBPs being up-regulated.

The first group (claudins; CLDNs) form the structural backbone of tight junctions (TJs), one type of cell-cell adhesion, and comprise at least 27 members of integral transmembrane proteins ranging in size from 20 to 34 kDa [12]. In recent years, the up- or down-modulated expression of several claudins has been associated with the progression of various cancers in humans, even in a tissue specific manner [12].

Interestingly, individual claudins are being used as therapeutic targets [44, 45] as well as diagnostic biomarkers [13, 14], making them a very interesting molecule to be investigated and characterized.

The second group of insulin like growth factor binding proteins (IGFBPs) differs in its importance from claudins, as they belong to the insulin-like growth factor (IGF) axis, which has a vital role in regulating cell survival and growth and is involved in several stages of cancer.

The expression of the two IGFBP genes, igfbp3 and igfbp7, was intensely upregulated at the beginning of liver colonization (days 3 and 6 after tumor implantation). Subsequently, however, this increased expression returned gradually to normal, hence we assume that the up-regulation of IGFBPs is essential for dissemination and homing of tumor cells into the liver during early metastasis formation. This strongly suggests that the tumor/metastasis microenvironment has a crucial impact on the regulation of igfbp3 and igfbp7. Furthermore, these results along with previous studies [28, 46–48] show that the balanced expression of IGFBP3 and IGFBP7 is very essential for several cellular functions as both, up- and down-regulation of these two genes were related to malignant properties. This further suggests that the aberrant expression of these two genes can be an early indicator of CRC progression.

**27**

*Experimental Results Help Shape the Development of Personalized Medicine...*

support the idea that IGFBP3 and IGFBP7 are multi-functional.

sion in CRC tissues as compared to the respective normal tissues [36].

Further verification of their value arises from studies that demonstrate involvement of the IGF axis in several stages of cancer and for its vital role in regulating cell and tissue survival, growth and differentiation [18, 19]. In addition, the possible use of constituents of this axis as tumor and/or metastasis markers is becoming the focus of increasing research activities [49–51]. Most *in vitro* studies, reported a tumor suppressor function of IGFBP3 and IGFBP7 through IGF-dependent and/or independent mechanisms [27, 31, 52, 53]. At variance to these studies, our experiments on silencing *IGFBP3* and *IGFBP*7 in three CRC cell lines uniformly show reduced proliferation, colony formation, and for *IGFBP3*, also reduced migration. Our observations are in agreement with few reports, which related IGFBP3 and IGFBP7 to growth promoting functions [28, 54]. Accordingly, these and our results

IGFBP3 is well known in the literature: It is the predominant IGFBP in plasma, hence plays a crucial role in regulating the bioavailability of plasma IGFs, and it is expressed locally in most tissues including the intestine [55]. Additionally, IGFBP3 induces apoptosis and inhibits proliferation in human colon [56], prostate [57], breast [58], and lung cancer cells [26] *in vitro* and in experimental CRC animal models [59]. Furthermore, wild type p53 can induce IGFBP3 expression [60], thus enhancing the p53-dependent apoptotic response of CRC cells to DNA damage [56]. Reduced levels of IGFBP3 and elevated circulating levels of IGF-I were associated with increased risk of prostate [61], breast [62], and colorectal [63, 64] cancers. Nevertheless, this association was not confirmed in all conducted studies [65–67]. It was observed that TGF-β can induce IGFBP3 and mediates its proliferative response in aggressive CRC cells, which exempts the studies reporting a tumor suppressor function of IGFBP3 [28].

In contrast to IGFBP3, the regulation and functions of IGFBP7 are less investigated. This gene was originally cloned as a gene, which is down-regulated in meningioma cell lines [68]. IGFBP7 is usually expressed by colonic mucosa [65], however both, up- and down-regulation patterns were recorded in the context of cancer [46, 47]. Lately, it was shown that IGFBP7 is a direct p53 target and the DNA methylation mediated-epigenetic silencing of IGFBP7 was associated with the absence of p53 mutations in CRC [30]. Until now, *in vitro* experiments demonstrated a negative effect of IGFBP7 on the growth of various cancer cells, including cervical carcinoma (HeLa) [69], osteosarcoma (Saos-2) [69], and breast [70]. Furthermore, in human CRC cell lines, expression of IGFBP7 was detectable in Caco2 and SW480 cells only, whereas its expression in invading tumor cells associated with poor prognosis in CRC patients [71]. In addition, immunohistochemistry and RT-PCR showed IGFBP7 over-expres-

As also known from the literature, several members of the IGF axis were found to be prognostic markers for various tumor types, including IGFBP5 and IGFBP7 for nonsmall cell lung cancer (NSCLC) [72], IGFBP2 and IGFBP3 as compensatory biomarkers for CA19-9 in early-stage pancreatic cancer [51], IGF-1 for metastatic uveal melanoma [49] and IGF-IR for glioblastoma [50]. In addition, a recent study showed that certain single nucleotide polymorphisms (SNPs) in IGF1R and IGF2R were associated (positively or inversely, respectively) with adenomas in Caucasian, but not in African American CRC patients [73]. Similarly, specific SNPs in the IGF-l gene were suggested as risk assessment markers of gastrointestinal cancers [74]. All these studies emphasize the crucial role of the patient's genetic background in tailoring the therapeutic approach to fit the "size" of this particular patient.

With regard to using the above family members as prognostic marker, the past experience should be considered. Contrasting with our expectations and reports from the literature, no significant correlation was found between the increased expression levels of four known tumor progression-associated genes (Opn, Tgf-β,

*DOI: http://dx.doi.org/10.5772/intechopen.80752*

*Experimental Results Help Shape the Development of Personalized Medicine... DOI: http://dx.doi.org/10.5772/intechopen.80752*

Further verification of their value arises from studies that demonstrate involvement of the IGF axis in several stages of cancer and for its vital role in regulating cell and tissue survival, growth and differentiation [18, 19]. In addition, the possible use of constituents of this axis as tumor and/or metastasis markers is becoming the focus of increasing research activities [49–51]. Most *in vitro* studies, reported a tumor suppressor function of IGFBP3 and IGFBP7 through IGF-dependent and/or independent mechanisms [27, 31, 52, 53]. At variance to these studies, our experiments on silencing *IGFBP3* and *IGFBP*7 in three CRC cell lines uniformly show reduced proliferation, colony formation, and for *IGFBP3*, also reduced migration. Our observations are in agreement with few reports, which related IGFBP3 and IGFBP7 to growth promoting functions [28, 54]. Accordingly, these and our results support the idea that IGFBP3 and IGFBP7 are multi-functional.

IGFBP3 is well known in the literature: It is the predominant IGFBP in plasma, hence plays a crucial role in regulating the bioavailability of plasma IGFs, and it is expressed locally in most tissues including the intestine [55]. Additionally, IGFBP3 induces apoptosis and inhibits proliferation in human colon [56], prostate [57], breast [58], and lung cancer cells [26] *in vitro* and in experimental CRC animal models [59]. Furthermore, wild type p53 can induce IGFBP3 expression [60], thus enhancing the p53-dependent apoptotic response of CRC cells to DNA damage [56]. Reduced levels of IGFBP3 and elevated circulating levels of IGF-I were associated with increased risk of prostate [61], breast [62], and colorectal [63, 64] cancers. Nevertheless, this association was not confirmed in all conducted studies [65–67]. It was observed that TGF-β can induce IGFBP3 and mediates its proliferative response in aggressive CRC cells, which exempts the studies reporting a tumor suppressor function of IGFBP3 [28].

In contrast to IGFBP3, the regulation and functions of IGFBP7 are less investigated. This gene was originally cloned as a gene, which is down-regulated in meningioma cell lines [68]. IGFBP7 is usually expressed by colonic mucosa [65], however both, up- and down-regulation patterns were recorded in the context of cancer [46, 47]. Lately, it was shown that IGFBP7 is a direct p53 target and the DNA methylation mediated-epigenetic silencing of IGFBP7 was associated with the absence of p53 mutations in CRC [30]. Until now, *in vitro* experiments demonstrated a negative effect of IGFBP7 on the growth of various cancer cells, including cervical carcinoma (HeLa) [69], osteosarcoma (Saos-2) [69], and breast [70]. Furthermore, in human CRC cell lines, expression of IGFBP7 was detectable in Caco2 and SW480 cells only, whereas its expression in invading tumor cells associated with poor prognosis in CRC patients [71]. In addition, immunohistochemistry and RT-PCR showed IGFBP7 over-expression in CRC tissues as compared to the respective normal tissues [36].

As also known from the literature, several members of the IGF axis were found to be prognostic markers for various tumor types, including IGFBP5 and IGFBP7 for nonsmall cell lung cancer (NSCLC) [72], IGFBP2 and IGFBP3 as compensatory biomarkers for CA19-9 in early-stage pancreatic cancer [51], IGF-1 for metastatic uveal melanoma [49] and IGF-IR for glioblastoma [50]. In addition, a recent study showed that certain single nucleotide polymorphisms (SNPs) in IGF1R and IGF2R were associated (positively or inversely, respectively) with adenomas in Caucasian, but not in African American CRC patients [73]. Similarly, specific SNPs in the IGF-l gene were suggested as risk assessment markers of gastrointestinal cancers [74]. All these studies emphasize the crucial role of the patient's genetic background in tailoring the therapeutic approach to fit the "size" of this particular patient.

With regard to using the above family members as prognostic marker, the past experience should be considered. Contrasting with our expectations and reports from the literature, no significant correlation was found between the increased expression levels of four known tumor progression-associated genes (Opn, Tgf-β,

*Advances in the Molecular Understanding of Colorectal Cancer*

medicine since the nineteenth century.

up", i.e. using biomarkers.

different *in vitro* studies.

modulated and IGFBPs being up-regulated.

to be investigated and characterized.

involved in several stages of cancer.

"If it were not for the great variability among individuals, medicine might as well be a science and not an art" with these words the famous Canadian physician Sir William Osler anticipated and acknowledged the concept of personalized

Personalized medicine aims to optimize and tailor preventive and therapeutic approaches in favor of the best outcome for each patient, by using genetics, proteomics, and biological information, including biomarkers [34]. It attempts to sub-categorize patients into different groups according to their "molecular make

Here we have used a rat model of liver metastasis to identify genes with importance

The selected model for this experiment is characterized by a defined metastatic proliferation-onset in rat liver after intra-portal inoculation of CC531 cancer cells. Consequently, this allows exploring the chronological modulation of gene expression, from the very beginning of cancer cell homing into the liver to their final colonization of the whole organ. The technique of cancer cell reisolation from rat liver permitted, for the first time, monitoring the expression profile of numerous

The initial observation of these studies was based on cDNA microarray analysis of CC531 colon cancer cells, which allowed selecting candidates from gene families with significant up- or down-regulation. These candidates were further analyzed by

We have been focusing on the detection and evaluation of biomarkers for the last decades [33, 35–43]. From the several gene groups, which were highly modulated in expression during liver colonization we focused on two families. Both were characterized by dramatic initial changes in expression, with claudins being down

The first group (claudins; CLDNs) form the structural backbone of tight junctions (TJs), one type of cell-cell adhesion, and comprise at least 27 members of integral transmembrane proteins ranging in size from 20 to 34 kDa [12]. In recent years, the up- or down-modulated expression of several claudins has been associated with the progression of various cancers in humans, even in a tissue specific manner [12].

Interestingly, individual claudins are being used as therapeutic targets [44, 45] as well as diagnostic biomarkers [13, 14], making them a very interesting molecule

The expression of the two IGFBP genes, igfbp3 and igfbp7, was intensely upregulated at the beginning of liver colonization (days 3 and 6 after tumor implantation). Subsequently, however, this increased expression returned gradually to normal, hence we assume that the up-regulation of IGFBPs is essential for dissemination and homing of tumor cells into the liver during early metastasis formation. This strongly suggests that the tumor/metastasis microenvironment has a crucial impact on the regulation of igfbp3 and igfbp7. Furthermore, these results along with previous studies [28, 46–48] show that the balanced expression of IGFBP3 and IGFBP7 is very essential for several cellular functions as both, up- and down-regulation of these two genes were related to malignant properties. This further suggests that the aberrant expression of these two genes can be an early indicator of CRC progression.

The second group of insulin like growth factor binding proteins (IGFBPs) differs in its importance from claudins, as they belong to the insulin-like growth factor (IGF) axis, which has a vital role in regulating cell survival and growth and is

for organ colonization, which could be used as biomarkers or therapeutic targets.

candidate genes from the whole genome in a time-dependent manner.

**3. Discussion**

**26**

Mmp-2 and Cox-2) and the prognostic value of these genes in CRC patients [43]. This raises an important to answer question, i.e. what would be the best procedure to apply personalized medicine effectively and reliably? Could it be a minimum number of (bio)-markers for each cancer type to be tested, or should it be a complex approach as high throughput genome sequencing, as it is increasingly performed?

Ideally, a few markers would be better suited regarding costs of analysis and time until a patient can benefit from the results. However, there are currently only few markers which succeeded to be applied accordingly. Therefore, even more methods are being approached to assess the specific changes inherent to the full genome.
